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Gy (2.2 Gy/day) to the clinical target volume for tumor and 
metastatic nodal station, 54 Gy (1.8 Gy/day) to the clinical 
negative neck region concomitantly in 30 fractions. 
Concurrent chemotherapy was given to 32 pts (cisplatin 75-
100 mg/m²/21 days for 25 pts, cisplatin 30-40 mg/m²/week 
for 5 pts and Cetuximab for 2). Possible correlation between 
Overall Cancer specific (OS) and GTV-PET Volumes (GTV-T+N, 
GTV-T, GTV-N) was also considered. 
 
Results: The median follow-up was 39.2 months (range: 3-
125); 27%, 62% and 11% pts has respectively never smoked, a 
smoking history of more than 10 packs/year and not assessed. 
36 pts completed the treatment as scheduled. Temporary 
treatment interruption due to acute toxicity, mainly 
mucosae, was observed in 5 patients. No grade 4 acute 
mucosae and skin toxicity was reported. Seventeen pts (46%) 
experienced grade 3 toxicity, mostly dermatitis and 
mucositis. Late grade 3 and 2 xerostomia was seen 
respectively in 3% and 32% pts. No grade 4 late toxicity was 
observed. The 3-year OS, Local disease-free Tumor (LTC), 
Local disease-free Nodal (LNC) and distant metastasis-free 
(DMFS) survivals were 87%, 83%, 89% and 92% respectively. 
Multivariate Cox regression analyses revealed that GTV-T+N 
and GTV-T are predictors for OS with a best-cut-off value 
equal to 30.9 cc (p=0.005) and 22.4 cc (p=0.038). 
 
Conclusion: The slightly accelerated dose escalation in 
oropharyngeal cancers to 18FDG-PET positive tumour sub-
volumes is likely to be safe even with concurrent 
chemotherapy. Very interesting 3-year OS and loco-regional 
disease control rate are obtained. The results of the present 
study suggest that GTV-PET has a predictive value for the SIB-
HT outcome. These findings may constitute the basis for 
more personalized treatments.  
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Purpose or Objective: There are limited and heterogeneous 
data on prognostic factors of locally advanced epithelial non 
glandular sinonasal cancer (ESNC) treated with multimodal 
treatment strategy. Prognosis of ESNC remains poor, with an 
overall 5-year survival rate of 30–50%. We analyzed a 
retrospective series of consecutive patients (pts) treated 
with IMRT at our institution, with a specific focus on the 
prognostic implications of clinical and treatment-related 
factors. 
 
Material and Methods: Since 2007, 49 pts with ESNC staged 
III and IVA-IVB were treated at our Institution. Histology was 
squamous cell carcinoma (SCC) in 22 pts (44.9%), 
undifferentiated carcinoma (SNUC) in 20 pts (40.8%) and 
neuroendocrine carcinoma (SNEC) in 7 pts (14.3%). Prevalent 
primary site was ethmoid sinus (24 pts, 49%). Thirteen pts 
(26.5%) had N stage ≥2b and 12 (24.5%) had positive 
retropharyngeal nodes (RPNs). Orbital apex invasion (OAI), 
nasopharyngeal involvement, gross nerves involvement (GNI) 
and positive surgical margins (R1) were found in 24 (49%), 12 
(24.5%), 10 (20.4%) and 5 (10.2%) pts respectively. Thirty 
(61.2%) and 19 (38.8%) pts received definitive and 
postoperative IMRT, respectively. Thirtyfive pts (71.5%) 
received induction chemotherapy before surgery or RT 
and/or concomitant CHT. Thirtyeight pts (77.5%) received 
concomitant CHT. IMRT was given with standard fractionation 
at a total dose of 65-72 Gy in definitive cases and 54-66 Gy in 
adjuvant cases, according to histological findings. Gross 
tumor volume (GTV) was defined in all radical pts, and dose-
volume histograms to all targets were analyzed in all pts. 
 
Results: Median follow up was 22.4 months (range 6-85). 
Three-year overall survival (OS), disease free survival (DFS) 
and locoregional control (LRC) were respectively 66.5%, 
55.4% and 66.3% for the entire cohort. OS and DFS were 
statistically better in pts with SCC or SNUC compared to pts 
with SNEC, in pts with ethmoid primary compared to other 
sites, in pts with N0 compared to pts with N stage ≥ 2b, in pts 
with RPNs compared to pts without RPNs (see Fig. 1), in pts 
with OAI compared to pts without OAI and in pts with GNI 
compared to pts without GNI. LRC was better even though 
statistically not different in pts without R1 compared to pts 
with R1. A multivariate analysis showed that ethmoid as 
primary origin site was a positive independent prognostic 
factor on OS, whereas RPNs positivity and OAI were negative 
independent prognostic factors for OS. For pts receiving 
definitive IMRT, pts with GTV <79.7cc had better OS, DFS and 
LRC compared to pts ≥79.7 cc, even if the difference was not 
statistically significant. Dosimetric factors were not found to 
have any prognostic role. 
 
 
 
Conclusion: In a monoinstitutional series of locally advanced 
ESNC we obtained a 66.5% 3-yr OS and a 55.4% 3-yr DFS. We 
were able to identify RPNs involvement, ethmoid primary site 
and OAI as independent prognostic factors.  
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Purpose or Objective: To compare early tumor response and 
compliance of locally advanced head and neck cancer 
patients receiving concurrent chemo-radiation, weekly 
Cisplatin with conventional fractionation versus weekly 
Cisplatin with accelerated fractionation and to assess toxicity 
profile 
 
Material and Methods: Patients with histologically confirmed 
primary head and neck squamous cell carcinoma, stage III and 
IV (Oral cavity, oropharynx, hypopharynx and larynx) 
attending the department of Radiotherapy, Father Muller 
Medical College Hospital, Mangalore Between November 2013 
to April 2015. 
Total of 64 patients were recruited and randomized into 
conventional and accelerated arm each having 32 patients. 
